New inhaled drug aims to fight deadly lung scarring
Disease control
Recruiting now
This Phase 2 trial tests an experimental inhaled medication called LTI-03 in about 120 people with idiopathic pulmonary fibrosis (IPF), a progressive lung disease that causes scarring and breathing difficulty. Participants will inhale LTI-03 or a placebo twice daily for 24 weeks.…
Phase 2 • Sponsor: Rein Therapeutics • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC